ArticleRespiratory research2026
HLA-DRA-mediated inhibition of T-Cell proliferation by differentiated airway epithelium and its disruption in smoking-associated airway inflammation.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHLA-DRA molecule is expressed in human airway epithelial cells (HAECs), but its specific functions remain unclear. This study mainly focused on HLA-DRA molecule’s contribution to the effect of airway epithelium on T-cell proliferation.
methodsHLA-DRA expression and its dynamics during airway epithelial differentiation were assessed in human tissues (immunohistochemistry/immunofluorescence) and air-liquid interface (ALI) cultures (TaqMan qPCR, Western blotting, immunofluorescence). We employed a co-culture model to evaluate the regulatory effect of differentiated airway epithelium on T-cell proliferation, with HLA-DRA’s role tested via neutralizing antibodies. The impact of cigarette smoke extract (CSE) on HLA-DRA and T-cell proliferation was examined. We further explored the therapeutic potential of restoring HLA-DRA by overexpressing its transcriptional regulator, POU domain class 2–associating factor 1(POU2AF1, also known as OCA-B or BOB.1/OBF.1). We also validated key findings using public single-cell RNA sequencing data.
findingsBoth in vivo and in vitro analyses confirmed that HLA-DRA expression is significantly upregulated during HAEC’s differentiation, with high levels detected in apical ciliated and secretory cells but minimal in basal cells. In the co-culture model, well-differentiated HAECs (ALI-day 21) potently suppressed the proliferation of pre-activated T cells, whereas undifferentiated cells (ALI-day 0) did not. This immunosuppressive effect was contact-dependent and was partially but significantly reversed by pre-treating HAECs with anti-HLA-DRA blocking antibodies. Exposure to CSE downregulated HLA-DRA expression in differentiated HAECs and, concurrently, attenuated their capacity to inhibit T cell proliferation. CSE reduced the expression of the transcription factor POU2AF1, and lentiviral overexpression of POU2AF1 partially rescued HLA-DRA expression in smoke-exposed epithelium.
conclusionsOur findings indicate a novel immunoregulatory function of airway epithelium, wherein HLA-DRA partially mediates the contact-dependent suppression of activated T cell proliferation, which may contribute to mucosal immune balance. Cigarette smoke disrupts this “epithelial brake” mechanism via downregulation of the POU2AF1–HLA-DRA axis, promoting excessive T cell expansion. These results implicate the POU2AF1–HLA-DRA axis in smoking-associated airway inflammation and highlight its potential as a therapeutic target for immune modulation in chronic airway diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.